Valuation Metrics and Recent Changes
As of 22 Sep 2026, Fredun Pharmaceuticals trades at ₹1,347.55, up 3.19% from the previous close of ₹1,305.85. The stock remains below its 52-week high of ₹1,600.00 but well above the 52-week low of ₹390.57, signalling strong price momentum over the past year. However, the valuation landscape has shifted considerably. The company’s P/E ratio stands at 51.33, a level that has pushed its valuation grade from fair to expensive. Similarly, the price-to-book value ratio has risen to 8.07, further underscoring the premium investors are currently paying for the stock.
Other valuation multiples reinforce this trend: the enterprise value to EBIT ratio is 23.93, and EV to EBITDA is 21.76, both indicating a relatively high valuation compared to earnings and cash flow. Despite these elevated multiples, the PEG ratio remains at a moderate 0.81, suggesting that earnings growth expectations may still justify some of the premium.
Comparative Analysis with Peers
When benchmarked against its peer group, Fredun Pharmaceuticals’ valuation appears expensive but not extreme. For instance, Ind-Swift Laboratories and Shukra Pharmaceuticals are rated as very expensive, with P/E ratios of 50.16 and 71.97 respectively, and EV to EBITDA multiples exceeding 48 and 50.12. Venus Remedies and Fermenta Biotec, on the other hand, maintain fair valuations with P/E ratios of 18.25 and 25.43, respectively.
Fredun’s valuation multiples place it in the upper tier of the sector but below the most expensive peers. This positioning reflects a market consensus that the company’s growth prospects and return metrics justify a premium, albeit with caution given the stretched multiples.
Crushing the market! This Small Cap from Aerospace & Defense just earned its spot in our Top 1% with impressive gains. Don't let this opportunity slip through your hands.
- - Recent Top 1% qualifier
- - Impressive market performance
- - Sector leader
Financial Performance and Returns Contextualised
Fredun Pharmaceuticals’ return profile over various time horizons has been exceptional, especially when compared to the broader Sensex index. Year-to-date, the stock has surged 156.14%, while the Sensex has declined 12.16%. Over the past year, Fredun’s return of 228.99% dwarfs the Sensex’s negative 9.40%. Even over a five-year period, the stock has delivered a staggering 765.48% return, vastly outperforming the Sensex’s 26.87% gain.
These returns reflect the company’s robust operational performance, supported by a return on capital employed (ROCE) of 19.94% and return on equity (ROE) of 15.95%. Such profitability metrics are strong indicators of efficient capital utilisation and shareholder value creation, which partly justify the premium valuation.
Sector and Market Capitalisation Considerations
Operating within the Pharmaceuticals & Biotechnology sector, Fredun is classified as a micro-cap stock. This classification often entails higher volatility and risk but also greater potential for outsized returns. The sector itself is characterised by rapid innovation, regulatory challenges, and evolving market dynamics, all of which influence valuation multiples.
Fredun’s valuation grade was recently downgraded from Strong Buy to Buy on 21 Sep 2026, reflecting the shift to an expensive valuation. The MarketsMOJO Mojo Score currently stands at 77.0, indicating a favourable but more cautious outlook. This adjustment signals that while the stock remains attractive, investors should be mindful of the stretched multiples and potential for valuation correction.
Valuation Versus Growth: Balancing Expectations
Despite the elevated P/E and P/BV ratios, the PEG ratio of 0.81 suggests that earnings growth is expected to remain robust. This metric, which adjusts the P/E ratio for growth, indicates that the stock is not excessively overvalued relative to its growth prospects. However, investors should consider that the PEG ratio is lower than some peers, such as TTK Healthcare’s 1.38, which is rated attractive, and Jagsonpal Pharma’s 2.37, which is very expensive.
Dividend yield remains negligible at 0.03%, signalling that the company prioritises reinvestment and growth over shareholder payouts. This is typical for growth-oriented pharmaceutical companies but may be a consideration for income-focused investors.
Want to dive deeper on Fredun Pharmaceuticals Ltd? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Investor Takeaway: Navigating Valuation and Growth Dynamics
Fredun Pharmaceuticals Ltd’s transition from fair to expensive valuation reflects the market’s recognition of its strong growth trajectory and solid financial performance. The company’s high P/E and P/BV ratios indicate that investors are willing to pay a premium, supported by robust returns and profitability metrics. However, the downgrade in valuation grade and the micro-cap status suggest that caution is warranted, particularly given the potential for valuation volatility in the sector.
Comparisons with peers reveal that while Fredun is expensive, it is not the most overvalued in its industry. Its PEG ratio below 1.0 implies that growth expectations remain a key driver of its valuation. For investors, this means balancing the allure of strong historical returns and growth prospects against the risks of stretched multiples and sector-specific challenges.
In summary, Fredun Pharmaceuticals remains a compelling buy within the Pharmaceuticals & Biotechnology sector, but the recent valuation shift calls for a measured approach. Monitoring earnings growth, sector developments, and market sentiment will be crucial for investors aiming to capitalise on the company’s potential while managing risk effectively.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
